Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Article Title: PD-L1 P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer.

doi: 10.1016/j.ymthe.2021.09.013

Figure Lengend Snippet: Figure 1. rs17718883 is associated with better overall survival in GC patients (A) GC patients with rs17718883 have higher overall survival (OS) rate and longer median survival time (MST) relative to counterparts with wild-type (WT) PD-L1. Ka- plan-Meier survival curve showing that the PD-L1 rs17718883 polymorphism correlates with OS in patients with GC. rs17718883 was detected in blood samples of 101 GC patients. (B) IHC analysis of PD-L1 expression in GC tissues. Representative images for PD-L1 expression. Magnification, 10; scale bar, 20 mm. (C and D) The protein expression profile is similar for PD-L1 WT and rs17718883. Correlation between PD-L1 expression level and rs17718883; correlation between rs17718883 and PD-L1 combined positive score (CPS). HR, hazard ratio; CI, confidence interval; ns, no significance.

Article Snippet: To investigate the effects of PD-L1 rs17718883 polymorphism on efficacy of PD-1/PD-L1 blockade therapy in GC cells, T cells were incubated with or without 1 ng/mL PD-1 antibody nivolumab (MedChem Express) for 4 days and then co-cultivated with indicated GC cells that labeled with the LIVE/DEAD Cell-Mediated Cytotoxicity Kit (Life Technologies), at a ratio of 10:1 for 6 h. The cell lysis was measured by flow cytometry.

Techniques: Expressing